Clinical efficacy of sparfloxacin in mycoplasmal pneumonia. A pilot study

Takahiko Horiguchi, Soichi Tachikawa, Junichi Miyazaki, Misuzu Handa

研究成果: Article査読

抄録

Sparfloxacin, a new synthetic quinolone antimicrobial agent, was administered to 20 patients with mycoplasmal pneumonia to evaluate its clinical efficacy and adverse effects. The efficacy rate was 100%. In all cases, the subjective symptoms, chest x-ray findings and inflammatory response improved within 5 days after sparfloxacin administration. There were no adverse events including abnormal laboratory values in any of the patients during the treatment period, and no adverse effects that were thought to be due to sparfloxacin were encountered. Since sparfloxacin displays an excellent activity against Mycoplasma pneumoniae and has a broad spectrum of antimicrobial activity against not only Gram-negative bacteria but also Gram-positive bacteria, Legionella, Chlamydia and acid-fast bacteria, it appears to be useful as the drug of first choice in the treatment of respiratory tract infections.

本文言語English
ページ(範囲)297-302
ページ数6
ジャーナルClinical Drug Investigation
15
4
DOI
出版ステータスPublished - 1998

All Science Journal Classification (ASJC) codes

  • 薬理学(医学)

フィンガープリント

「Clinical efficacy of sparfloxacin in mycoplasmal pneumonia. A pilot study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル